Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
Authors:
- Lucia CerritoLCLucia Cerrito
- Maria Elena AinoraMAMaria Elena Ainora
- Raffaele BorrielloRBRaffaele Borriello
- Giulia PiccirilliGPGiulia Piccirilli
- Matteo GarcovichMGMatteo Garcovich
- Laura RiccardiLRLaura Riccardi
- Maurizio PompiliMPMaurizio Pompili
- Antonio GasbarriniAntonio Gasbarrini
- Maria Assunta ZoccoMZMaria Assunta Zocco
Open Access
Abstract
Intrahepatic cholangiocarcinoma (iCCA) represents the second most common liver cancer after hepatocellular carcinoma, accounting for 15% of primary liver neoplasms. Its incidence and mortality rate have been rising during the last years, and total new cases are expected to increase up to 10-fold during the next two or three decades. Considering iCCA’s poor prognosis and rapid spread, early diagnosis is still a crucial issue and can be very challenging due to the heterogeneity of tumor presentation at imaging exams and the need to assess a correct differential diagnosis with other liver lesions. Abdominal contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) plays an irreplaceable role in the evaluation of liver masses. iCCA’s most typical imaging patterns are well-described, but atypical features are not uncommon at both CT and MRI; on the other hand, contrast-enhanced ultrasound (CEUS) has shown a great diagnostic value, with the interesting advantage of lower costs and no renal toxicity, but there is still no agreement regarding the most accurate contrastographic patterns for iCCA detection. Besides diagnostic accuracy, all these imaging techniques play a pivotal role in the choice of the therapeutic approach and eligibility for surgery, and there is an increasing interest in the specific imaging features which can predict tumor behavior or histologic subtypes. Further prognostic information may also be provided by the extraction of quantitative data through radiomic analysis, creating prognostic multi-parametric models, including clinical and serological parameters. In this review, we aim to summarize the role of contrast-enhanced imaging in the diagnosis and management of iCCA, from the actual issues in the differential diagnosis of liver masses to the newest prognostic implications.Keywords
This publication has 119 references indexed in Scilit:
- Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosisJournal of Hepatology, 2013
- Evaluation of Biliary Malignancies Using Multidetector-Row Computed TomographyJournal of Computer Assisted Tomography, 2010
- Clinical usefulness of 18F-FDG PET-CT for patients with gallbladder cancer and cholangiocarcinomaJournal of Gastroenterology, 2009
- Intrahepatic CholangiocarcinomaAnnals of Surgery, 2008
- Peripheral Mass–Forming Cholangiocarcinoma in Cirrhotic LiverAmerican Journal of Roentgenology, 2007
- [F-18]Fluorodeoxyglucose Positron Emission Tomography and Positron Emission TomographyJournal of Computer Assisted Tomography, 2007
- Cholangiocarcinoma: Modern advances in understanding a deadly old diseaseJournal of Hepatology, 2006
- Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinomaJournal of Hepatology, 2006
- CT evaluation of paraaortic lymph node metastasis in patients with biliary cancerJournal of Gastroenterology, 2005
- Contrast‐enhanced MR imaging of intrahepatic cholangiocarcinoma: Pathologic correlation studyJournal of Magnetic Resonance Imaging, 1995